.webp)
67/100BRoyalty Pharma P/E ratioWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
Royalty Pharma's P/E ratio is 39.81: its share price of 67.29 over its earnings per share of 1.69 over the last twelve months.
- Today
- 39.81
- Forward P/E, next 12 months
- 11.53
- PEG ratio
- 0.49
- Median, 5 years
- 20.49
- Low, 5 years
- 8.25
- High, 5 years
- 3,021.00
P/E ratio = price ÷ EPS (last 12 months) = 67.29 ÷ 1.69 = 39.81
Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.
The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.
Is Royalty Pharma's P/E high compared with its own history?Is the P/E high or low for this stock? Today's P/E against every daily P/E of the stock's last 5 years, with the growth analysts expect: whether the stock is expensive or cheap compared with itself, and whether its growth explains it.
Royalty Pharma's P/E of 39.8 is above the middle of its 5-year range (8.2 to 3,021.0, median 20.5). Analysts expect faster growth than in recent years, which can explain part of the high P/E.
A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.
P/E ratio by year and by quarter
| Fiscal year | Period ending | P/E ratio | Forward P/E | Market cap | Net income |
|---|---|---|---|---|---|
| FY2027 · Estimate | 31 Dec 2027 | 11.38 | — | — | — |
| FY2026 · Estimate | 31 Dec 2026 | 12.48 | — | — | — |
| Today | 39.81 | 11.53 | 29.96B | — | |
| FY2025 | 31 Dec 2025 | 12.60 | 7.16 | 16.69B | 1.32B |
| FY2024 | 31 Dec 2024 | 8.55 | 5.51 | 11.38B | 1.33B |
| FY2023 | 31 Dec 2023 | 7.40 | 6.94 | 12.57B | 1.70B |
| FY2022 | 31 Dec 2022 | 75.23 | 9.33 | 17.31B | 230.06M |
| FY2021 | 31 Dec 2021 | 13.32 | — | 16.53B | 1.24B |
| FY2020 | 31 Dec 2020 | 11.41 | — | 19.43B | 1.70B |
| FY2019 | 31 Dec 2019 | 6.40 | — | 15.76B | 2.46B |
| FY2018 | 31 Dec 2018 | 10.38 | — | 15.76B | 1.52B |
| FY2017 | 31 Dec 2017 | 11.73 | — | 15.76B | 1.34B |
| FY2016 | 31 Dec 2016 | 47.73 | — | 27.01B | 565.91M |
| FY2015 | 31 Dec 2015 | 46.46 | — | 27.01B | 581.43M |
| Quarter | Period ending | P/E ratio | Forward P/E | Market cap | Net income |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | — | 10.10 | 25.97B | — |
| Q2 FY2026 | 30 Jun 2026 | 31.19 | 9.92 | 24.95B | 800.12M |
| Q1 FY2026 | 31 Mar 2026 | 17.48 | 8.69 | 20.72B | 1.19B |
| Q4 FY2025 | 31 Dec 2025 | 12.60 | 7.16 | 16.69B | 1.32B |
| Q3 FY2025 | 30 Sept 2025 | 11.70 | 6.78 | 15.24B | 1.30B |
| Q2 FY2025 | 30 Jun 2025 | 9.17 | 7.19 | 15.26B | 1.66B |
| Q1 FY2025 | 31 Mar 2025 | 7.67 | 6.46 | 13.56B | 1.77B |
| Q4 FY2024 | 31 Dec 2024 | 8.55 | 5.51 | 11.38B | 1.33B |
| Q3 FY2024 | 30 Sept 2024 | 7.36 | 6.31 | 12.62B | 1.71B |
| Q2 FY2024 | 30 Jun 2024 | 11.47 | 6.08 | 11.81B | 1.03B |
| Q1 FY2024 | 31 Mar 2024 | 11.30 | 7.25 | 13.41B | 1.19B |
| Q4 FY2023 | 31 Dec 2023 | 7.40 | 6.94 | 12.58B | 1.70B |
| Q3 FY2023 | 30 Sept 2023 | 32.68 | 6.63 | 12.17B | 372.47M |
| Q2 FY2023 | 30 Jun 2023 | 29.41 | 7.42 | 13.85B | 470.81M |
| Q1 FY2023 | 31 Mar 2023 | 26.27 | 8.60 | 16.06B | 611.07M |
| Q4 FY2022 | 31 Dec 2022 | 75.89 | 9.33 | 17.46B | 230.06M |
| Q3 FY2022 | 30 Sept 2022 | 19.75 | — | 17.65B | 893.77M |
| Q2 FY2022 | 30 Jun 2022 | 20.49 | — | 18.34B | 895.15M |
| Q1 FY2022 | 31 Mar 2022 | 13.97 | — | 16.91B | 1.21B |
| Q4 FY2021 | 31 Dec 2021 | 13.53 | — | 16.80B | 1.24B |
| Q3 FY2021 | 30 Sept 2021 | 9.96 | — | 15.48B | 1.55B |
| Q2 FY2021 | 30 Jun 2021 | 8.58 | — | 16.78B | 1.96B |
| Q1 FY2021 | 31 Mar 2021 | 9.70 | — | 17.00B | 1.75B |
| Q4 FY2020 | 31 Dec 2020 | 11.41 | — | 19.43B | 1.70B |
| Q3 FY2020 | 30 Sept 2020 | — | — | 15.57B | — |
| Q2 FY2020 | 30 Jun 2020 | — | — | 17.19B | — |
| Q1 FY2020 | 31 Mar 2020 | — | — | 15.60B | — |
| Q4 FY2019 | 31 Dec 2019 | — | — | 15.68B | — |
| Q3 FY2019 | 30 Sept 2019 | — | — | 15.76B | — |
| Q2 FY2019 | 30 Jun 2019 | — | — | 15.76B | — |
| Q1 FY2019 | 31 Mar 2019 | — | — | 15.76B | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.
See also:Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios
Common questions about Royalty Pharma's P/E ratio
Source: Financial Modeling Prep